LON:VAL ValiRx (VAL) Share Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free VAL Stock Alerts GBX 2.95 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range 2.91▼ 350-Day Range 1.90▼ 452-Week Range 1.85▼ 15Volume265,000 shsAverage Volume1.37 million shsMarket Capitalization£3.90 millionP/E RatioN/ADividend Yield0.63%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ValiRx alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About ValiRx Stock (LON:VAL)ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.Read More VAL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAL Stock News HeadlinesMay 30 at 5:16 AM | americanbankingnews.comValiRx (LON:VAL) Trading 11.1% Higher May 26, 2024 | morningstar.comValiRx PLC VALMay 20, 2024 | lse.co.ukLONDON MARKET CLOSE: London gets boost thanks to rate cut hopesMay 20, 2024 | lse.co.ukValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grantMay 16, 2024 | lse.co.ukEARNINGS AND TRADING: Tullow Oil on track to hit free cash flow targetMay 15, 2024 | lse.co.ukTRADING UPDATES: Vertu Motors ups dividend as hails record revenueFebruary 28, 2024 | msn.comNew method discovered to halt active cancer cellsFebruary 27, 2024 | uk.news.yahoo.comScientists discover 'two-punch' method to eliminate cancer cellsFebruary 13, 2024 | lse.co.ukValiRx says requisition notice from shareholder group is invalidFebruary 9, 2024 | lse.co.ukTRADING UPDATES: ValiRx receives shareholder request for board changeDecember 5, 2023 | markets.businessinsider.comEuropean Stocks Close Mostly HigherDecember 5, 2023 | markets.businessinsider.comEuropean Markets Move Mostly HigherDecember 5, 2023 | lse.co.ukValiRx says ValiSeek inks deal to licence VAL401 drug with AmbroseNovember 15, 2023 | morningstar.comValiRx PLC EAJFNovember 10, 2023 | lse.co.ukValiRx signs deal to evaluate StingRay Bio drug candidatesOctober 6, 2023 | lse.co.ukCORRECT (Oct 5): ICG Enterprise ups interim payout on better resultsOctober 6, 2023 | lse.co.ukValiRx sees no reason for shares jump; notes TheoremRx mulls mergerSeptember 11, 2023 | finance.yahoo.comVAL.L - ValiRx plcAugust 24, 2023 | lse.co.ukValiRx interim loss widens as costs increase; hails Inaphaea progressAugust 24, 2023 | marketwatch.comValiRx Shares Rise on Higher Income Expectations From Inaphaea BioLabsAugust 14, 2023 | lse.co.ukValiRx signs collaborative services agreement with AgilityAugust 14, 2023 | marketwatch.comValiRx Shares Rise After Collaborative Services Agreement With AgilityJuly 19, 2023 | marketwatch.comValiRx Shares Rise After Subsidiary Secures ContractJune 28, 2023 | lse.co.ukTRADING UPDATES: All Things Considered raises funds to buy SandbagJune 16, 2023 | lse.co.ukValiRx shares drop after cancer drug research droppedSee More Headlines Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/07/2020Today6/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:VAL CUSIPN/A CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.23% Return on Assets-40.43% Debt Debt-to-Equity Ratio0.76 Current Ratio2.64 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow62.50 Book ValueGBX 3 per share Price / Book0.98Miscellaneous Outstanding Shares132,350,000Free FloatN/AMarket Cap£3.90 million OptionableNot Optionable Beta0.63 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Suzanne J. Dilly B.Sc. (Age 46)BSc, Ph.D., CEO & Director Comp: $154.6kMr. James Gerry Desler FCA (Age 79)CFO, Company Secretary & Executive Director Comp: $66.45kMr. Kumar NawaniHead of OperationsDr. Catherine Jane Tralau-Stewart Ph.D.Chief Scientific Officer & Board ObserverMr. Mark TreharneCorporate Development ManagerDr. Andrew CarnegieHead of Strategic Commercial DevelopmentMore ExecutivesKey CompetitorsNetScientificLON:NSCIDestiny PharmaLON:DESTSynairgenLON:SNGRealm TherapeuticsLON:RLMGenflow BiosciencesLON:GENFView All Competitors VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed in 2024? ValiRx's stock was trading at GBX 5.90 on January 1st, 2024. Since then, VAL shares have decreased by 50.0% and is now trading at GBX 2.95. View the best growth stocks for 2024 here. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) earnings per share for the quarter. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR). How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:VAL) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport Society“This will be one of the biggest revolutions ever.” - NVIDIA CEOBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.